Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: A Prospective Study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 5, 2015, Pages 514-519

  Lombardi, Giuseppe ^a   Rumiato, Enrica ^b   Bertorelle, Roberta ^b   Saggioro, Daniela ^b   Farina, Patrizia ^a   Puppa, Alessandro Della ^b   Zustovich, Fable ^a   Berti, Franco ^b   Sacchetto, Valeria ^b   Marcato, Raffaella ^b   Amadori, Alberto ^b   Zagonel, Vittorina ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

DMET; Glioblastoma; MGMT; Polymorphism; Temozolomide; Toxicity

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450 REDUCTASE; METHIONINE ADENOSYLTRANSFERASE; METHIONINE ADENOSYLTRANSFERASE 1A; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTON PUMP INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC VARIABILITY; GLIOBLASTOMA; HEMATOPOIETIC CELL; HEREDITY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMICALLY INDUCED; CHEMORADIOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HEMATOLOGIC DISEASE; MONONUCLEAR CELL; RADIATION RESPONSE;

ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HEMATOLOGIC DISEASES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84941881183     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182a790ea     Document Type: Article

References (27)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
2. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf. 2009; 8: 493-499.
3. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
4. Sabharwal A, Waters R, Danson S, et al. Predicting the myelotoxicity of chemotherapy: The use of pretreatment O6- methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res. 2011; 21: 502-508.
5. Armstrong TS, Cao Y, Scheurer ME, et al. Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors. Neuro Oncol. 2009; 11: 825-832.
6. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60: 5954-5958.
7. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59: 793-797.
8. Huang SH, Chang PY, Liu CJ, et al. O6-methylguanine-DNA methyltransferase gene coding region polymorphisms and oral cancer risk. J Oral Pathol Med. 2010; 39: 645-650.
9. Dumaual C, Miao X, Daly TM, et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics. 2007; 8: 293-305.
10. Rabbee N, Speed TP. A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics. 2006; 22: 7-12.
11. Guzzi PH, Agapito G, Di Martino MT, et al. DMET-analyzer: Automatic analysis of Affymetrix DMET data. BMC Bioinformatics. 2012; 13: 258.
12. Gerber DE, Grossman SA, Zeltzman M, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol. 2007; 9: 47-52.
13. Dixit S, Baker L, Walmsley V, et al. Temozolomide-related idiosyncratic and other uncommon toxicities: A systematic review. Anticancer Drugs. 2012; 23: 1099-1106.
14. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992; 22: 1-21.
15. Burchell B, Brierley CH, Rance D. Specificity of human UDPglucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 1995; 57: 1819-1831.
16. Nakada M, Furuta T, Hayashi Y, et al. The strategy for enhancing temozolomide against malignant glioma. Front Oncol. 2012; 2: 98.
17. Bobustuc GC, Baker CH, Limaye A, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol. 2010; 12: 917-927.
18. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13: 707-715.
19. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13: 916-926.
20. Lombardi G, Bellu L, Berti F, et al. Efficacy and safety of radiotherapy plus temozolomide in elderly patients with glioblastoma. J Clin Oncol. 2013; 31(suppl; abstr 2043).
21. Bugni JM, Han J, Tsai MS, et al. Genetic association and functional studies of major polymorphic variants of MGMT. DNA Repair (Amst). 2007; 6: 1116-1126.
22. Gerson SL, Miller K, Berger NA. O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest. 1985; 76: 2106-2114.
23. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 1004-1011.
24. Kokkinakis DM, Liu X, Chada S, et al. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res. 2004; 64: 7513-7525.
25. Masters BS. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem Biophys Res Commun. 2005; 338: 507-519.
26. Soneda S, Yazawa T, Fukami M, et al. Proximal promoter of the cytochrome P450 oxidoreductase gene: Identification of microdeletions involving the untranslated exon 1 and critical function of the SP1 binding sites. J Clin Endocrinol Metab. 2011; 96: E1881-E1887.
27. Tee MK, Huang N, Damm I, et al. Transcriptional regulation of the human P450 oxidoreductase gene: Hormonal regulation and influence of promoter polymorphisms. Mol Endocrinol. 2011; 25: 715-731.